Biopharma Co. to Launch Two Clinical Trials This Year
  (5/14/22)
Success in either program, atopic dermatitis or asthma, "could lead to multiblockbuster sales," noted a ROTH Capital Partners report. More >

Japan Pharma Co. Invests $275 Million in U.S. Oncology Firm
Source: Streetwise Reports  (5/13/22)
Cullinan Oncology Inc. shares traded 23% higher yesterday after the company reported it entered into a strategic investment, development, and licensing agreement with Taiho Pharmaceutical Co. Ltd. of Japan for its CLN-081/TAS6417 for use in treatment of non-small cell lung cancer. More >

First Results From Biotech Co.'s Lymphoma Program Are Impressive
  (5/13/22)
This data will be presented at the 2022 annual meeting of the European Hematology Association on June 11th, noted a ROTH Capital Partners report. More >

Pfizer Offers $11.6B to Buy Biopharma Co.
Source: Streetwise Reports  (5/10/22)
Shares of Biohaven Pharmaceutical Holding Co. Ltd. traded almost 70% higher after the company reported it agreed to be acquired by Pfizer Inc. for $148.50 per share in cash plus future royalty opportunities. More >

Ophthalmic Med Tech. Firm Sees 166% Gain in LAL Implants
Source: Streetwise Reports  (5/6/22)
Shares of RxSight Inc. traded 7% higher after the company reported Q1/22 financial results which highlighted a 157% YoY increase in revenue and a 208% increase in unit sales of its Light Delivery Devices (LDDâ„¢s) utilized in cataract surgery procedures to implant its RxSight Light Adjustable Lens® (LAL), which it says is "the world's first and only adjustable intraocular lens (IOL) that is customized after cataract surgery." More >

Analyst Says Avivagen Is a Strong Buy
Source: Clive Maund  (5/5/22)
With Avivagen's breakthrough product relishing in its success, Analyst Clive Maund reviews if he believes it is now a formidable contender as a Buy. More >

Biopharma Co. Licenses Orphan Drug to UK Firm for $450M
Source: Streetwise Reports  (5/5/22)
Intercept Pharmaceuticals Inc. shares traded 20% higher after the company reported it entered into a $450 million licensing agreement with Advanz Pharma in markets outside of the U.S. for Ocaliva® for use in treatment of primary biliary cholangitis, a progressive and chronic autoimmune disease which affects the liver. More >

Pilot Launch of VLN Cigarettes in Progress
  (5/3/22)
These "very low nicotine" tobacco products will be an alternative for smokers when the FDA effects its imminent menthol cigarette ban, noted a ROTH Capital Partners report. More >

FDA Expands Use for Transcarotid Stent
Source: Streetwise Reports  (5/2/22)
Silk Road Medical Inc. shares traded 12% higher after the company reported that the U.S. FDA granted expanded authorization for its ENROUTE® transcarotid stent system for use in preventing stroke in patients deemed to be at standard risk for adverse events from carotid endarterectomy. More >

Biotech Co. Advances COVID-19 Vaccines Toward Approval
  (5/1/22)
They include booster vaccines for different age groups of children and an Omicron-targeting booster for adults, noted an H.C. Wainwright & Co. report. More >

Is Reliq Health Technologies a Nutrimental 'Buy'?
Source: Clive Maund  (4/29/22)
After recovering from a short "character assassination," Reliq Health Technologies may be on the up-and-up. Clive Maund examines the latest data from the company to see if it would make a good 'buy'. More >

Could a New Prescription Drug Treat This Common Ailment?
  (4/27/22)
The combination drug Halo-Lido is poised to be the first-of-its-kind prescription treatment approved by the U.S. Food and Drug Administration for this prevalent medical condition, noted a DawsonJames report. More >

Biopharma Co. Posts 32% YoY Gain in Proprietary Sales
Source: Streetwise Reports  (4/27/22)
Alkermes Plc. shares traded 12% higher after the Ireland-based company reported Q1/22 financial results and reiterated its FY/22 business outlook. More >

Biopharma Co. Posts Positive Data in Ph. 1 Cancer Trials
Source: Streetwise Reports  (4/25/22)
Nkarta Inc. shares traded over 120% higher after the company reported positive dosing data from two separate Phase 1 clinical trials evaluating the use of natural killer cell therapies to target r/r acute myeloid leukemia and myelodysplastic syndrome and r/r B cell malignancies. More >

FDA Grants RMAT Status for T-Cell Therapy for Six Viruses
Source: Streetwise Reports  (4/20/22)
Shares of AlloVir Inc. traded 18% higher after the firm reported that the U.S. FDA awarded Regenerative Medicine Advanced Therapy designation to its posoleucel for use in preventing life-threatening infections from six viruses in allogeneic hematopoietic cell transplant patients. More >

Senior Biotech Analyst's Top 3 Stocks
Source: Streetwise Reports  (4/19/22)
Streetwise Reports recently spoke to renowned biotech expert John Vandermosten (CFA) about three of his favorite healthcare companies that are addressing as-of-yet unmet market needs. More >

Biotech Co.'s Shares Quadruple on $250M Buyout Bid
Source: Streetwise Reports  (4/19/22)
Shares of Checkmate Pharmaceuticals Inc. traded 330% higher to a new 52-week high after the company reported it agreed to be acquired by Regeneron Pharmaceuticals Inc. for $10.50 per share in cash. More >

Life Sciences Co. Expected to Attract Partners, Big Pharma
  (4/19/22)
"We foresee continued execution on its developmental strategy," noted Argus Research on this development stage biotech company tackling neurodegenerative diseases. More >

EU PE Firm Makes $1.2B Bid for US Medical Device Co.
Source: Streetwise Reports  (4/18/22)
Shares of Natus Medical Inc. traded 29% higher after the company reported it agreed to be acquired by ArchiMed Group, a France-based private equity firm, for $33.50 per share in cash. More >

Vaccine Maker Awarded Approval for COVID-19 Vaccine
Source: Streetwise Reports  (4/14/22)
Shares of Valneva SE traded 8.5% higher after the company reported that the U.K.'s MHRA has granted Conditional Marketing Authorization for its inactivated whole-virus COVID-19 vaccine candidate called VLA2001 for primary immunization in adults between 18 and 50 years old. More >

GSK Offers $1.9B for Cancer-Focused Pharma Co.
Source: Streetwise Reports  (4/13/22)
Shares of Sierra Oncology Inc. traded 38% higher after the company reported it agreed to be acquired by GlaxoSmithKline Plc. for $55 per share in cash. More >

Cannabis Firm Increases YOY Revenue By 352% in 2021
  (4/12/22)
The company is expected to outperform again in 2022 given its focus on strategic growth and acquisitions, noted a Noble Capital Markets report. More >

Biopharma Firm Signs $452M License Deal for BMT Drug
Source: Streetwise Reports  (4/12/22)
Shares of Actinium Pharmaceuticals Inc. traded 24% higher after the company reported it entered into a licensing and supply agreement for its antibody radiation conjugate, Iomab-B, with Sweden's Immedica Pharma AB for sales in Europe, the Middle East and North Africa. More >

Novel Drug Reduces COVID-19 Deaths by 55% in Ph. 3 Trial
Source: Streetwise Reports  (4/11/22)
Shares of Veru Inc. traded 180% higher after company reported interim data from a Phase 3 clinical study of its COVID-19 drug candidate sabizabulin which was shown to reduce deaths in hospitalized patients by 55%. More >

Co. Uses Protein Modulation to Treat Cancer
Source: Streetwise Reports  (4/9/22)
Nurix Therapeutics Inc. shares traded 13% higher after the company reported Q1/22 financial results and released an outline for two poster presentations that will be submitted at the American Association for Cancer Research Annual Meeting this weekend. More >